Se trata de la primera ronda de financiación privada más grande cerrada por una start-up en España.
➡️bit.ly/2CbW4sR
La ronda ha sido liderada por @AsabysPartners y cuenta con la participación de @_AltaLS, @YsiosCapital, FundPlus Belgium y BPI France. La empresa centra su actividad en el desarrollo de un nuevo medicamento para el tratamiento del cáncer metastásico.
L'spin-off va sorgir arran d'uns resultats publicats per #SalvadorAznarBenitah a @nature el 2017 que demostren que el bloqueig de les rutes del metabolisme dels greixos prevé la formació de metàstasi i és potencialment capaç d'eliminar les ja existents.
➡️bit.ly/30MIkyQ
Aquests resultats es reprodueixen en un gran nombre de models animals de #càncer, entre ells càncer oral, de mama, d'ovari, gàstric, de bufeta, de pròstata i melanoma entre d'altres.
The financing will allow @OnaTherapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🔬An international consortium, led by #IRBBarcelona & the biotech company @MerusNV, reports the discovery of MCLA-158, the first clinical candidate screened in #organoids targeting 🎯 #cancer#stemcells of solid tumors.
Named Petosemtamab, the antibody MCLA-158 prevents the onset of #metastasis (that is, the spread of #cancer to other vital organs) and slows the growth of primary tumours in experimental models of cancer.
The study also lays the groundwork for the use of #organoids in the #DrugDiscovery process undertaken by pharmaceutical companies.
Organoids are patient-derived samples that can be grown in the laboratory, and they reproduce certain aspects of the tumour compartment.
#IRBScience: Published in @GenomeMedicine, the latest work from the SBNB lab points to the co-occurrence of #cancer driver genes as a key to precision medicine.
The system is called Targeted Cancer Therapy for You (TCT4U), and it's aimed at predicting tumour response to different treatments.💊
It has allowed the identification of a set of complex biomarkers🧬that have now been made available to the medical-scientific community.
(2/4)↘️
"The sum of two or more mutated #Cancer driver genes affects the tumour's response to treatments" says @ptck72, "through this work, we see that studying cancer driver genes as a whole can bring about a great advance towards precision medicine".
@Eduard_puig is one of the committed scientists who recently made an important contribution to the field.
(1/4)
In June, @Eduard_puig, @SoniaCiudad and Natalia Carulla, among others, revealed the specific ensembles of Aβ protein that have the capacity to disrupt the membrane of neurons, causing their death.
@IRBBarcelona coordinates the European Project Evomet to train 15 young scientists and future leaders in metastasis research with the aim to identify therapeutic solutions. The project has received €4 M and will last for four years.
Each of the institutions will host one of the selected young researchers and will train them until they complete their doctorate, except for @IRBBarcelona and @idibell_cat IDIBELL, which will host two predoctoral researchers each.
#IRBScience: The @bbglab publishes "A compendium of mutational cancer driver genes" in @NatureRevCancer, with mportant implications in clinical decision making.
📢568 genes identified with the potential to trigger #cancer!
The study stands on the analysis of the genomes of 28,000 tumours from 66 types of cancer and it's a major update of the #IntOGen platform (intogen.org), aimed at identifying mutational cancer driver genes.
(2/5)
“The compendium of driver genes provides cancer researchers, both in the clinical and basic research setting, with crucial knowledge and it has an important impact on clinical decision-making,” says @nlbigas, head of the @bbglab at @IRBBarcelona and @icreacommunity.